共 50 条
- [21] Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trialLANCET ONCOLOGY, 2021, 22 (11): : 1597 - 1608DiNardo, Courtney D.Schuh, Andre C.Stein, Eytan M.Montesinos, PauWei, Andrew H.de Botton, StephaneZeidan, Amer M.Fathi, Amir T.Kantarjian, Hagop M.Bennett, John M.Frattini, Mark G.Martin-Regueira, PatriciaLersch, FrederikGong, JingHasan, MaroofVyas, PareshDoehner, Hartmut
- [22] Risk Stratified Treatment for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase 1/2 Non-Randomized Study of Trametinib and Azacitidine with or without ChemotherapyBLOOD, 2023, 142Stieglitz, ElliotChi, Yueh-YunChang, Bill H.Tasian, Sarah K.Yohe, MarielleDvorak, Christopher C.Southworth, EricaLong-Boyle, Janel R.Van Ziffle, JessicaAbdullaev, ZiedLeong, RoyWayne, Alan S.Bhojwani, DeepaLoh, Mignon L.
- [23] Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2-a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive ChemotherapyBLOOD, 2020, 136Zeidan, Amer M.Boddu, PrajwalWood, Brent L.Zelterman, DanielLittle, Richard F.Ivy, S. PercyCaldwell, AnneSanchez-Espiridion, BeatrizAlatrash, GheathSharon, EladRadich, Jerald P.
- [24] Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master TrialBLOOD, 2021, 138Patel, PraptiRuppert, Amy S.Borate, UmaStein, Eytan M.Baer, Maria R.Stock, WendyKovacsovics, TiborBlum, WilliamArellano, Martha L.Schiller, Gary J.Olin, Rebecca L.Foran, James M.Litzow, Mark R.Lin, Tara L.Foster, Matthew C.Redner, Robert L.Al-Mansour, ZeinaCogle, Christopher R.Boyiadzis, Michael M.Swords, RonanCollins, Robert H.Vergilio, Jo-AnneHeerema, Nyla A.Rosenberg, LeonardYocum, Ashley OwenMarcus, SonjaChen, TimothyDruggan, FranchescaStefanos, MonaGana, Theophilus J.Shoben, Abigail B.Druker, Brian J.Burd, AmyByrd, John C.Levine, Ross L.Mims, Alice S.
- [25] Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing TrialBLOOD, 2021, 138Wang, Eunice S.Altman, Jessica K.Minden, Mark D.Wu, RuishanRich, Elizabeth ShimaHill, Jason E.
- [26] Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AMLBLOOD, 2020, 136Lachowiez, CurtisKonopleva, MarinaKadia, Tapan M.Daver, NavalLoghavi, SanamWang, Sa A.Adeoti, MariaPierce, Sherry A.Takahashi, KoichiShort, Nicholas J.Sasaki, KojiBorthakur, GautamIssa, Ghayas C.Wierda, William G.Pemmaraju, NaveenBravo, Guillermo MontalbanFerrajoli, AlessandraJain, NitinMasarova, LuciaYilmaz, MusaJabbour, EliasGarcia-Manero, GuillermoKornblau, Steven M.Ravandi, FarhadKantarjian, Hagop M.Dinardo, Courtney D.
- [27] Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)BLOOD, 2024, 144 : 737 - 738Stempel, Jessica M.Uy, Geoffrey L.Dinner, Shira N.Gojo, IvanaReed, DanielRoy, RupaliByrd, Kenneth P.Yerrabothala, SwaroopaLai, Catherine E.Doucette, KimberleyCaldwell, AnneBlaha, OndrejPodoltsev, Nikolai A.Mendez, Lourdes M.Bewersdorf, Jan PhilippKewan, TariqWistuba, IgnacioAlatrash, GheathHaymaker, Cara L.Streicher, HowardSharon, EladMph, Richard Little M. D.Gore, Steven D.Radich, Jerald P.Mdphd, Brent L. WoodZeidan, Amer M.Shallis, Rory M.
- [28] Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/RelapseBLOOD, 2024, 144 : 736 - 737Arora, SankalpSenapati, JayastuLoghavi, SanamReville, Patrick K.Wang, BofeiKadia, Tapan M.Dinardo, Courtney D.Pemmaraju, NaveenYilmaz, MusaJabbour, Joseph E.Short, Nicholas J.Montalban-Bravo, GuillermoMaiti, AbhishekTang, GuilinSasaki, KojiBorthakur, GautamAlvarez, JoiePierce, SherryGonzalez, Graciela M. NoguerasNing, JingIssa, Ghayas C.Andreeff, MichaelRavandi, FarhadGarcia-Manero, GuillermoAbbas, Hussein A.Daver, Naval
- [29] Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)BLOOD, 2017, 130DiNardo, Courtney D.Stein, Anthony S.Fathi, Amir T.Montesinos, PauOdenike, OlatoyosiKantarjian, Hagop M.Stone, Richard M.Koralek, Daniel O.Van Oostendorp, JasonGong, JingGupta, IraVyas, Paresh
- [30] Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master TrialBLOOD, 2020, 136Stein, Eytan M.Huang, YingBorate, UmaBaer, Maria R.Stock, WendyKovacsovics, TiborBlum, WilliamSchiller, Gary J.Olin, Rebecca L.Foran, James M.Litzow, MarkLin, TaraPatel, Prapti A.Foster, Matthew C.Boyiadzis, MichaelCollins, Robert H.Vergilio, Jo-AnneHeerema, Nyla A.Rosenberg, LeonardYocum, Ashley OwenChen, TimothyDruggan, FranchescaMarcus, SonjaStefanos, MonaChervin, JordanShoben, AbigailDruker, Brian J.Burd, AmyByrd, John C.Levine, Ross L.Mims, Alice S.